Through this partnership, the companies – DexCom, Glooko, myDiabby Healthcare and Roche – will provide diabetes management platforms that are well-suited with Lilly’s Tempo Pen and Tempo Smart Button to help manage diabetes.

Approved in various markets across the globe, the Tempo Pen is a version of the company’s prefilled, disposable insulin pen. The Tempo Smart Button, which attaches to this pen, is yet to receive CE mark.

The Tempo Smart Button will be used with Dexcom, Glooko, myDiabby Healthcare and Roche’s software and/or medical devices. A combination of the pen and Roche’s mySugr app is expected to enable personalised data and actionable insights.

Eli Lilly connected care and insulins product development vice-president Marie Schiller said: “Insulin dose logging is often an incomplete piece of the diabetes management puzzle for people who use insulin pens and manually track their doses.

“By integrating data from the connected insulin pen solutions into widely used compatible software, including potential future collaborations, we aim to support improved decision-making for people with diabetes and their healthcare providers with accurate, real-time data collection.”

Lilly hopes that these solutions could aid in addressing psychological barriers such as fear of hypoglycaemia that could affect diabetes management negatively.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Studies demonstrated that using smart insulin devices with digital health tools improves outcomes for diabetes patients, Glooko CEO Russ Johannesson noted.

Lilly plans to obtain CE mark for the Tempo Smart Button later this year. On receiving this approval, the company will commercialise the Tempo Pen and Tempo Smart Button in various global markets.